Note: This message is displayed if (1) your browser is not standards-compliant or (2) you have you disabled CSS. Read our Policies for more information.
Overdose is common among persons who use illicit opioids such as heroin and among persons who misuse medications prescribed for pain, such as oxycodone and hydrocodone. Senate Enrolled act 227 went into effect March 2014 and provides immunity for first responders to utilize naloxone (Narcan), medication that counteracts the effects of an opioid drug overdose, including heroin. As of June 1, 2015, the use of Naloxone administered by law enforcement has saved at least 138 lives in Indiana.
Indiana Code allows first responders, which includes law enforcement officers, to administer Narcan/Naloxone to suspected victims of an overdose. Narcan will stop the overdose and save a life. Click below to watch a video designed to help first responders understand the immunity provided to them, the importance of implementing a Narcan program, and where to get additional information.
Indiana Naloxone Project: Yellow
Call: 812-320-7525 or email firstname.lastname@example.org
Health and Hospital Corporation of Marion County: Blue
At the 2015 Prescription Drug Abuse Symposium, AG Zoeller announced a grant program, funded by a recent pharmaceutical settlement reached between the Attorney General's Office and Amgen for deceptive drug promotion. The new grant will fund a surge in naloxone distribution, with the goal of ensuring all first responders are equipped with the life-saving treatment and trained to administer it. Nonprofits registered with ISDH to distribute naloxone kits and provide training on the use of naloxone to law enforcement and other first responders can apply for grant funding from the Attorney General's Office. Click here to download an application.
The Attorney General's Office is accepting applications for the grants now through Dec. 1, 2015. Grants will be awarded at the start of 2016.
For more information on the grant program and the full Request for Proposal, click here.